Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20997581 | 0.91 | ALDH1A1 (0.44) | POLBNPSR1L3MBTL1PTPN1KDM4E | |
| SCHEMBL12384441 | 0.84 | POLB (0.56) | POLBNPSR1L3MBTL1PTPN1KDM4E | |
| SCHEMBL17471229 | 0.78 | POLB (0.49) | POLBNPSR1L3MBTL1PTPN1KDM4E | |
| SCHEMBL15247326 | 0.78 | EPHX2 (0.44) | CYP2C19EPHX2DPP4DPP8DPP9 | |
| SCHEMBL23308180 | 0.76 | DPP4 (0.43) | EPHX2DPP4DPP8DPP9DPP7 | |
| SCHEMBL20192242 | 0.76 | PTPN1 (0.44) | POLBNPSR1L3MBTL1PTPN1KDM4E | |
| SCHEMBL22874720 | 0.74 | EPHX2 (0.58) | EPHX2DPP4DPP8DPP9 | |
| SCHEMBL15247300 | 0.74 | EPHX2 (0.58) | EPHX2DPP4DPP8DPP9 | |
| SCHEMBL25091884 | 0.73 | JAK2 (0.37) | POLBNPSR1L3MBTL1PTPN1KDM4E | |
| SCHEMBL15474138 | 0.73 | EPHX2 (0.45) | CYP2C19EPHX2DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | POLB 4110/4885NPSR1 721/4885L3MBTL1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.